Gilead Sciences Inc

Stock Chart, Company Information, and Scan Results

$152.67(as of Sep 22, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Gilead Sciences Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$152.67
Ticker SymbolGILD
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - General
Employees17,000
CountyUSA
Market Cap$186,129.7M
EBIDTA14,601.0M
10-Day Moving Average147.55
P/E Ratio-58.57
20-Day Moving Average147.67
Forward P/E Ratio15.29
50-Day Moving Average139.71
Earnings per Share-2.66
200-Day Moving Average133.97
Profit Margin-134.51%
RSI66.62
Shares Outstanding1,240.0M
ATR3.60
52-Week High154.51
Volume4,947,873
52-Week Low105.84
Most Recent Support Level148.22
Book Value11,744.0M
Most Recent Resistance Level153.23
P/B Ratio16.16
Upper Keltner155.77
P/S Ratio6.23
Lower Keltner139.57
Debt-to-Equity Ratio2.22
Next Earnings Date10/29/2026
Cash Surplus-7,841.0M
Next Ex-Dividend DateUnknown

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.